Cost-effectiveness analysis for midostaurin versus standard of care in acute myeloid leukemia in the United Kingdom

Overview of attention for article published in Cost Effectiveness and Resource Allocation, October 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (82nd percentile)
Good Attention Score compared to outputs of the same age and source (68th percentile)

Mentioned by

blogs: 1 blog
policy: 1 policy source

twitter: 1 X user

Citations

dimensions_citation: 13 Dimensions

Readers on

mendeley: 61 Mendeley

Summary Blogs Policy documents X Dimensions citations

So far, Altmetric has seen 1 blog post.

Cost-effectiveness analysis for midostaurin versus standard of care in acute myeloid leukemia in the United Kingdom

information for practice, 05 Oct 2018

Midostaurin (MIDO) has been proposed for the treatment of newly-diagnosed adult patients with FMS-like tyrosine kinase 3…

This page shows the most recent blog posts that mention this research output.

Click here to find out how to access more activity.